Low-dose oral methotrexate for maintaining Crohn's disease remission: where we stand.

@article{Sun2005LowdoseOM,
  title={Low-dose oral methotrexate for maintaining Crohn's disease remission: where we stand.},
  author={John Hoshyn Sun and Kiron M Das},
  journal={Journal of clinical gastroenterology},
  year={2005},
  volume={39 9},
  pages={
          751-6
        }
}
  • J. H. Sun, K. Das
  • Published 2005
  • Medicine
  • Journal of clinical gastroenterology
Methotrexate has been considered a second-line immunomodulating therapy, behind azathioprine (AZA) or its metabolite 6-mercaptopurine (6-MP), for the treatment of Crohn's disease (CD). Approximately 27% to 50% of patients with refractory CD are intolerant or resistant to AZA or 6-MP. Two well-designed randomized double-blind placebo-controlled trials have demonstrated that low-dose methotrexate (<25 mg/wk), given intramuscularly (IM), is effective in inducing and maintaining remission in CD. In… Expand
Use of methotrexate in refractory Crohn's disease: The Edinburgh experience
TLDR
Parenteral MTX therapy is efficacious in inducing remission in steroid‐dependent CD patients, although its use is limited by side effects in ≈30% of patients, and low‐dose oral therapy does not maintain long‐term remission and is not a suitable alternative. Expand
Methotrexate Following Unsuccessful Thiopurine Therapy in Pediatric Crohn's Disease
TLDR
Methotrexate appears effective in maintaining remission in pediatric Crohn's disease, when thiopurines have failed, and consideration should be given to its use earlier in pediatric treatment algorithms. Expand
Methotrexate Treatment in Pediatric Crohn Disease Patients Intolerant or Resistant to Purine Analogues
TLDR
Methotrexate is beneficial in maintaining remission and steroid-sparing treatment in children with Crohn disease following failure of thiopurine therapy. Expand
Efficacy of oral methotrexate in paediatric Crohn’s disease: a multicentre propensity score study
TLDR
In this largest paediatric CD cohort to date, SC administered MTX was superior to PO, but only in some of the outcomes and with a modest effect size; it may be reasonable to consider switching children in complete remission treated with subcutaneous MTX to the oral route with close monitoring of inflammatory markers and growth. Expand
MEDICAL THERAPY OF CROHN ’ S DISEASE : A REVIEW OF RECENT INNOVATIONS —
Crohn’s disease (CD) affects approximately 500 000 Americans, usually striking between the ages of 15 and 35 years. Before 1998, when the first tumor necrosis factor (TNF)-α antagonist was approvedExpand
Methotrexate for induction of remission in refractory Crohn's disease.
TLDR
This systematic review is an update of previously published Cochrane reviews and found that methotrexate patients were significantly more likely to enter remission than 5-ASA patients. Expand
Methotrexate for maintenance of remission in Crohn's disease.
TLDR
A systematic review of randomized trials examining the efficacy and safety of methotrexate for maintenance of remission in Crohn's disease found that Methotrexate may provide a safe and effective alternative to more expensive maintenance treatment with TNF-α antagonists. Expand
Specific considerations in the treatment of pediatric inflammatory bowel disease
TLDR
This review will outline the epidemiology and clinical complications that are unique to pediatric inflammatory bowel disease, current trends, and recent advances in nutritional and pharmacologic treatment, and projected future therapeutic direction. Expand
Transgenic rescue of methotrexate-induced teratogenicity in Drosophila melanogaster.
  • J. Affleck, V. Walker
  • Biology, Medicine
  • Toxicological sciences : an official journal of the Society of Toxicology
  • 2007
TLDR
The majority of key transcripts that were affected in MTX-exposed females including transcripts involved in cell cycle, defense response, and transport were "rescued" in the "MTX-resistant" transgenic flies, illustrating the utility of this invertebrate model for the investigation of molecular effects of MTX. Expand
Low dosages: new chemotherapeutic weapons on the battlefield of immune-related disease
TLDR
The immune regulatory roles of three kinds of chemotherapeutic drugs under low-dose conditions are discussed and low dosages are proposed as potential new chemotherAPEutic weapons on the battlefield of immune-related disease. Expand
...
1
2
...

References

SHOWING 1-10 OF 51 REFERENCES
Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial.
TLDR
Methotrexate at a weekly oral dose of 12.5 mg was found to be moderately better than 6-mercaptopurine and placebo in patients with chronic active CD. Expand
Methotrexate in Crohn's disease: long-term efficacy and toxicity
TLDR
This study suggests a long-term benefit of maintenance treatment with methotrexate in patients with chronically active Crohn's disease, with side effects that are usually only moderate. Expand
Low Dose Methotrexate in Inflammatory Bowel Disease: Current Status and Future Directions
TLDR
It is concluded that low dose methotrexate is an effective and safe treatment in glucocorticoid-dependent and thiopurine intolerant patients with Crohn's disease but not ulcerative colitis. Expand
Methotrexate in Crohn's disease: long-term efficacy and toxicity.
TLDR
A long-term benefit of maintenance treatment with methotrexate in patients with chronically active Crohn’s disease, with side effects that are usually only moderate is suggested. Expand
Low-dose methotrexate in rheumatic diseases--efficacy, side effects, and risk factors for side effects.
TLDR
Low-dose methotrexate (MTX) is a second-line agent of high potency with a favorable profile of safety and tolerability in the treatment of rheumatoid arthritis and preliminary reports on its beneficial effects in other disorders, including the systemic manifestations of RA, other spondyloarthritides, and collagen vascular diseases, merit more detailed examination. Expand
Low-dose oral methotrexate in refractory inflammatory bowel disease
TLDR
It is concluded that oral methotrexate may be useful and reasonably safe as a steroid-sparing agent in patients with refractory IBD. Expand
Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial.
TLDR
The methotrexate-treated group showed a trend toward fewer Crohn's disease flares, balanced by an increased number of significant side effects. Expand
DOUBLE-BLIND WITHDRAWAL TRIAL OF AZATHIOPRINE AS MAINTENANCE TREATMENT FOR CROHN'S DISEASE
51 patients with Crohn's disease who were in good health while taking azathiprine, 2 mg/kg body-weight/day, for at least six months were allocated either to a group in which azathioprine wasExpand
Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study.
TLDR
It is confirmed that methotrexate is effective in inducing remission in patients with chronic active Crohn's disease, therapeutic efficacy being comparable, but not faster, than that of azathioprine. Expand
Methotrexate in refractory Crohn's disease.
TLDR
Parenteral methotrexate appeared to be effective in inducing a clinical response in 70% of azathioprine-resistant or -intolerant CD patients and often permitted corticosteroid tapering, with an acceptable short-term toxicity. Expand
...
1
2
3
4
5
...